The Spine Journal
Volume 11, Issue 6 , Pages 560-567, June 2011

Biomimetic calcium phosphate coatings as bone morphogenetic protein delivery systems in spinal fusion

  • Kamran Majid, MD

      Affiliations

    • Department of Orthopaedic Surgery, William Beaumont Hospital, Royal Oak, MI, USA
  • ,
  • Michael D. Tseng, MD

      Affiliations

    • Department of Orthopaedic Surgery, William Beaumont Hospital, Royal Oak, MI, USA
  • ,
  • Kevin C. Baker, MS

      Affiliations

    • Department of Orthopaedic Research, William Beaumont Hospital, Research Institute, Suite, Royal Oak, MI, USA
    • Corresponding Author InformationCorresponding author. Department of Orthopaedic Research, William Beaumont Hospital, Research Institute, Suite 404, 3601 West Thirteen Mile Rd, Royal Oak, MI 48073, USA. Tel.: (248) 551-9726; fax: (248) 551-0191.
  • ,
  • Alma Reyes-Trocchia, MD

      Affiliations

    • Department of Pathology, William Beaumont Hospital, Royal Oak, MI, USA
  • ,
  • Harry N. Herkowitz, MD

      Affiliations

    • Department of Orthopaedic Surgery, William Beaumont Hospital, Royal Oak, MI, USA

Received 14 July 2009; received in revised form 10 September 2009; accepted 2 December 2009. published online 25 January 2010.

Abstract 

Background context

Use of recombinant human bone morphogenetic protein-2 (rhBMP-2) has been shown to enhance spinal fusion rates. Case reports of soft-tissue swelling, ectopic bone formation, and osteolysis have recently surfaced. It is hypothesized that incorporation of rhBMP-2 within a calcium phosphate (CaP) coating may help to localize delivery and mitigate these complications.

Purpose

To compare the characteristics of posterolateral fusion between rabbits receiving rhBMP-2 delivered via physical adsorption to a collagen sponge or rhBMP-2 incorporated within the physical structure of a CaP coating on a collagen sponge.

Study design/setting

New Zealand white rabbit model of posterolateral lumbar fusion at L5–L6.

Methods

Eighteen (18) New Zealand white rabbits underwent posterolateral spinal fusion at L5–L6. Rabbits received bilateral collagen sponges that were either coated with CaP (n=3), coated with CaP and dipped in rhBMP-2 (n=3), coated with a hybrid CaP–rhBMP-2 film (n=6), or coated with a hybrid CaP-rhBMP-2 film and dipped in rhBMP-2 (n=6). Animals were followed weekly with radiographs and were sacrificed at 6 weeks. Fusion masses were further characterized by manual palpation, computed tomography, and histology.

Results

Radiographic evaluation showed that animals in Group 3 (incorporated BMP) fused at 4 weeks, whereas animals in Group 2 (adsorbed BMP) and Group 4 (incorporated and adsorbed BMP) fused by 6 weeks. Animals that received rhBMP-2 physically adsorbed to the collagen sponge showed extension of the fusion mass beyond the L5–L6 level in 56% of cases and bone resorption in 78%. Histology of fusion masses showed mature bone formation in animals belonging to Groups 2, 3, and 4 and extensive osteoclast recruitment in animals belonging to Groups 2 and 4.

Conclusions

Delivery of rhBMP-2 via incorporation within CaP coatings results in increased rates of radiographic fusion. The burst release profile of rhBMP-2 adsorbed to surfaces, although effective in achieving fusion, may result in increased osteoclast recruitment.

Keywords: rhBMP-2, Bone graft substitute, Drug delivery, Animal model, Calcium phosphate

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 FDA device/drug status: Not applicable (animal study).

 Author disclosures: KM: Nothing to disclose. MDT: Nothing to disclose. KCB: Nothing to disclose. AR-T: Nothing to disclose. HNH: Nothing to disclose.

 This work was funded by the William Beaumont Hospital Research Institute.

PII: S1529-9430(09)01120-6

doi:10.1016/j.spinee.2009.12.006

The Spine Journal
Volume 11, Issue 6 , Pages 560-567, June 2011